The C.D.C. recommends that other vaccines be preferred over J.&J.

The agency’s advisers cited concerns about the increased incidence of a rare but potentially serious blood clotting condition among those who received the company’s shot.The agency’s advisers cited concerns about the increased incidence of a rare but potentially serious blood clotting condition among those who received the company’s shot.Blood Clots, Vaccination and Immunization, Coronavirus (2019-nCoV), Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention, Food and Drug Administration, Johnson & JohnsonRead More

Leave a Reply

Your email address will not be published.